13F-HR filed by Avoro Capital Advisors LLC
Avoro Capital Advisors LLC filed this 13F-HR for the quarter ended 2025-06-30, filed 2025-08-14, with 30 holding rows worth $5,710,277,507.
- Accession
- 0001104659-25-078127
- Filer
- CIK 1633313
- Filed
- 2025-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2025
A holdings report, 30 entries on the cover page, a total value of $5,710,277,507 stated on the cover page (in dollars after the unit check, H1), rows summing to $5,710,277,507 with VALUE read as dollars as filed, 13F file number 028-16573. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ASCENDIS PHARMA A/S DKK 1.0 AD | 04351P101 | SPONSORED ADR | 4,980,000 | $859,548,000 | dollars as filed | |
| UNITED THERAPEUTICS CORP DEL COM | 91307C102 | Stock | 2,370,000 | $681,019,500 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 1,175,000 | $647,683,500 | dollars as filed | |
| MADRIGAL PHARMACEUTICALS INC COM | 558868105 | Stock | 1,875,000 | $567,450,000 | dollars as filed | |
| KRYSTAL BIOTECH INC COM | 501147102 | Stock | 2,660,000 | $365,643,600 | dollars as filed | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 6,555,555 | $286,084,420 | dollars as filed | |
| APELLIS PHARMACEUTICALS INC | 03753U106 | COM | 12,222,222 | $211,566,663 | dollars as filed | |
| AVIDITY BIOSCIENCES INC COM | 05370A108 | Stock | 7,050,000 | $200,220,000 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 4,150,000 | $195,880,000 | dollars as filed | |
| AKERO THERAPEUTICS INC | 00973Y108 | COM | 3,500,000 | $186,760,000 | dollars as filed | |
| SOLENO THERAPEUTICS INC | 834203309 | COM | 2,050,000 | $171,749,000 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 5,400,000 | $169,020,000 | dollars as filed | |
| ARROWHEAD PHARMACEUTICALS IN | 04280A100 | COM | 10,600,000 | $167,480,000 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 3,155,555 | $165,982,193 | dollars as filed | |
| VERA THERAPEUTICS INC | 92337R101 | COMMON STOCK | 6,300,000 | $148,428,000 | dollars as filed | |
| AMICUS THERAPEUTICS INC | 03152W109 | COM | 18,000,000 | $103,140,000 | dollars as filed | |
| ALKERMES PLC | G01767105 | SHS | 2,900,000 | $82,969,000 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 7,400,000 | $68,672,000 | dollars as filed | |
| 89BIO INC | 282559103 | COM | 6,750,000 | $66,285,000 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 5,000,000 | $65,700,000 | dollars as filed | |
| UNIQURE NV | N90064101 | SHS | 3,625,000 | $50,532,500 | dollars as filed | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 21,700,000 | $50,127,000 | dollars as filed | |
| BLUEPRINT MEDICINES CORP | 09627Y109 | COM | 375,000 | $48,067,500 | dollars as filed | |
| Tourmaline Bio Inc | 89157D105 | Common Stock | 2,555,555 | $40,863,324 | dollars as filed | |
| BIOCRYST PHARMACEUTICALS INC COM | 09058V103 | Stock | 4,500,000 | $40,320,000 | dollars as filed | |
| MANNKIND CORP COM NEW | 56400P706 | Stock | 5,850,000 | $21,879,000 | dollars as filed | |
| MONTE ROSA THERAPEUTICS INC | 61225M102 | COM | 3,725,000 | $16,799,750 | dollars as filed | |
| SEPTERNA INC COM | 81734D104 | Stock | 1,237,500 | $13,080,375 | dollars as filed | |
| ULTRAGENYX PHARMACEUTICAL IN | 90400D108 | COM | 330,000 | $11,998,800 | dollars as filed | |
| WHITEHAWK THERAPEUTICS INC | 00032Q104 | CMN | 2,849,402 | $5,328,382 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-25-078127 | this filing | 2025-08-14 | acceptance time not in the bulk data set |